A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors

Inclusion Criteria

• Males and females at least 18 years of age
• Histologically- or cytologically- confirmed solid tumor (except melanoma) that is metastatic or unresectable
• Advanced or metastatic cancer for which no standard therapy exists or that has progressed despite standard therapy
• Acceptable organ and marrow function during the Screening Period as defined by the protocol.
• Reliable venous access suitable for weekly study drug infusions
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Exclusion Criteria

• Pregnant or breast-feeding women
• Have had chemotherapy or radiotherapy within 4 weeks prior to entering the study
• Primary brain tumors or active brain metastases
• Treatment with chronic immunosuppressants
• Significant cardiovascular disease, severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration